SCHEMBL6089352

SCHEMBL6089352

CC(=O)Nc1ccc2c(c1)/C(=C1/C(=O)Nc3ccc(Cl)cc31)OC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.51
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GSK3B P49841 3/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
PDPK1 O15530 1/20 0.42
IDO1 P14902 2/20 0.42
TDO2 P48775 2/20 0.42
TGM2 P21980 2/20 0.42
KDR P35968 4/20 0.42
PPIA P62937 1/20 0.41
BRAF P15056 1/20 0.40
PKM P14618 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NOX4 Q9NPH5 1/20 0.39
CCNE2 O96020 1/20 0.39
EGFR P00533 1/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089358 1.00 LRRK2 (0.51) LRRK2MEN1KMT2AGSK3BALDH1A1
SCHEMBL6087556 0.92 LRRK2 (0.51) LRRK2MEN1KMT2AGSK3BPDPK1
SCHEMBL6087551 0.92 LRRK2 (0.51) LRRK2MEN1KMT2AGSK3BPDPK1
SCHEMBL6105082 0.87 ALDH1A1 (0.47) MEN1KMT2AGSK3BALDH1A1GAA
SCHEMBL6105079 0.87 ALDH1A1 (0.47) MEN1KMT2AGSK3BALDH1A1GAA
SCHEMBL14725035 0.87 MEN1 (0.44) LRRK2MEN1KMT2AALDH1A1HTT
SCHEMBL6087302 0.87 MEN1 (0.44) LRRK2MEN1KMT2AALDH1A1HTT
SCHEMBL14725106 0.87 MEN1 (0.44) LRRK2MEN1KMT2AIDO1TDO2
SCHEMBL6086501 0.87 MEN1 (0.44) LRRK2MEN1KMT2AIDO1TDO2
SCHEMBL6086496 0.87 MEN1 (0.44) LRRK2MEN1KMT2AIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP claimed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US claimed
US-6541504-B1 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN SALES, LLC 2003-04-01 US claimed
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
US-6541504-B1 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN SALES, LLC 2003-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 LRRK2 545/4885MEN1 3222/4885KMT2A 1161/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 LRRK2 497/4885MEN1 3309/4885KMT2A 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.